Unión Europea - español - EMA (European Medicines Agency)

accord healthcare s.l.u. - lenalidomida - mieloma múltiple - inmunosupresores - multiple myelomalenalidomide accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) está indicado para el tratamiento de pacientes adultos no tratados previamente con mieloma múltiple que no son elegibles para el trasplante. la lenalidomida acuerdo en combinación con dexametasona está indicado para el tratamiento de mieloma múltiple en pacientes adultos que han recibido al menos una terapia previa. follicular lymphomalenalidomide accord in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

celltrion, inc. corea, republica de - rituximab 10 mg/ml - concentrado para soluciÓn para perfusiÓn - cada ml contiene: rituximab 10 mg

Unión Europea - español - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Unión Europea - español - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - inmunosupresores - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

farmindustria s.a. - clorhidrato de memantina; - tableta recubierta - por ; rituximab 100.000000 mcg; - rituximab

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

promociones farmaceuticas s.a. en liquidacion - por ; rituximab 10.000000 mg; - rituximab

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

astrazeneca peru s.a. - comprimido - por ; rituximab 100.000000 mg; - rituximab

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - bortezomib - excipientes: manitol (e-421) - otros agentes antineoplÁsicos - otros agentes antineoplásicos - bortezomib

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sandoz farmaceutica, s.a. - bortezomib - excipientes: manitol (e-421) - otros agentes antineoplÁsicos - otros agentes antineoplásicos - bortezomib

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

accord healthcare s.l.u. - bendamustina hidrocloruro - polvo para concentrado para soluciÓn para perfusiÓn - 100 mg - bendamustina hidrocloruro 100 mg - bendamustina